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Neuropathic pain is still an extremely important problem in today’s medicine because
opioids, which are commonly used to reduce pain, have limited efficacy in this type
of pathology. Therefore, complementary therapy is needed. Our experiments were
performed in rats to evaluate the contribution of the purinergic system, especially
P2X4 receptor (P2X4R), in the modulation of glia activation and, consequently, the
levels of nociceptive interleukins after chronic constriction injury (CCI) of the right
sciatic nerve, a rat model of neuropathic pain. Moreover, we studied how intrathecal
(ith.) injection of a P2X4R antagonist Tricarbonyldichlororuthenium (II) dimer (CORM-
2) modulates nociceptive transmission and opioid effectiveness in the CCI model. Our
results demonstrate that repeated ith. administration of CORM-2 once daily (20 µg/5 µl,
16 and 1 h before CCI and then daily) for eight consecutive days significantly reduced
pain-related behavior and activation of both spinal microglia and/or astroglia induced by
CCI. Moreover, even a single administration of CORM-2 on day 7 after CCI attenuated
mechanical and thermal hypersensitivity as efficiently as morphine and buprenorphine. In
addition, using Western blot, we have shown that repeated ith. administration of CORM-
2 lowers the CCI-elevated level of MMP-9 and pronociceptive interleukins (IL-1β, IL-18,
IL-6) in the dorsal L4-L6 spinal cord and/or DRG. Furthermore, in parallel, CORM-2
upregulates spinal IL-1Ra; however, it does not influence other antinociceptive factors,
IL-10 and IL-18BP. Additionally, based on our biochemical results, we hypothesize that
p38MAPK, ERK1/2 and PI3K/Akt but not the NLRP3/Caspase-1 pathway are partly
involved in the CORM-2 analgesic effects in rat neuropathic pain. Our data provide new
evidence that P2X4R may indeed play a significant role in neuropathic pain development
by modulating neuroimmune interactions in the spinal cord and DRG, suggesting that
its blockade may have potential therapeutic utility.
Keywords: antinociceptive interleukins, buprenorphine, chronic constriction injury, CORM-2, morphine,
neuropathy, p38MAPK, PI3K/Akt
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INTRODUCTION
The neuropathic pain state, which can occur after injury of a
nerve or be a concurrent symptom of various clinical disorders,
is considered to be one of the most important problems
in medicine today (Burma et al., 2016; Burke et al., 2017).
The limited understanding of its pathomechanism prevents
the development of an effective treatment. Opioid drugs, used
commonly in clinics for inflammatory pain therapy, lose their
efficacy in neuropathic pain (Furlan et al., 2006). In recent years,
a rising number of reports have confirmed the crucial role of
microglial cells in neuropathic pain development (Tsuda et al.,
2003; Beggs and Salter, 2013). Those cells have been shown
to be strongly activated after peripheral nerve injury on the
ipsilateral side of the spinal cord (Tsuda et al., 2003; Beggs and
Salter, 2013). This is directly connected with the morphological
changes of microglia into an amoeboid form and the enhanced
expression of nociceptive factors and microglial receptors levels
(Beggs and Salter, 2013). Matrix metalloproteinase 9 (MMP-
9) appears to induce the development of neuropathic pain by
active cleavage of IL-1β and activating p38MAPK in spinal
microglia (Schonbeck et al., 1998; Kawasaki et al., 2008). While
activated, microglial cells are known to release pronociceptive
cytokines (for instance IL-1β, IL-6, and IL-18), which cause
pain and counteract opioid analgesia (DeLeo and Yezierski,
2001; Mika et al., 2008; Narita et al., 2008). Recently, many
studies have highlighted the crucial role of antinociceptive
cytokines (IL-1Ra, IL-10, and IL-18BP) against pain (Ledeboer
et al., 2007; Mika et al., 2013; Pilat et al., 2015, 2016). We,
as well as other laboratories, have previously reported that
inhibiting microglia activation with minocycline significantly
reduces pain behavior and the level of pronociceptive interleukins
and enhances the effectiveness of morphine in neuropathy
(Mika et al., 2007; Cui et al., 2008; Zychowska et al.,
2016).
Certain subtypes of purinergic ionotropic (P2X) receptors
are reported to contribute to neuropathic pain development
(Tsuda et al., 2003; Grygorowicz et al., 2016). We decided to
take a close look at microglial subtype 4 (P2X4R) because
of the increasing number of studies indicating its importance
in neuropathy pathogenesis when activated by its endogenous
agonist, adenosine, 5′-triphosphate (ATP) (Sim and North,
2010). Elevated levels of this nucleotide are observed after
injuries, which induce the depolarization of sensory neurons
(North and Khakh, 2006). The role of ATP was examined
in various contexts, e.g., in knock-out mouse models or
pharmacomodulation (Cockayne et al., 2000; Tsuda et al., 2003).
Ulmann et al. (2008) examined P2X4 knockout mice, which
showed a remarkable reduction in mechanical hypersensitivity
after spinal nerve injury in comparison with wild-type animals.
P2X4R might thus represent a potential therapeutic target
to limit microglia-mediated inflammatory responses associated
with nervous system injury (Ulmann et al., 2008). There is
abundant evidence that extracellular ATP plays an important
role in pain signaling in both the peripheral and central
nervous system. It has been demonstrated that extracellular
ATP and/or its metabolites are factors possibly involved in the
transduction of mechanical stimuli into enhanced excitability
of nociceptive nerve fibers in the trunk of a peripheral nerve,
and it is well-documented that ATP is released by different
types of mechanical stimuli (Irnich et al., 2002; Lazarowski
et al., 2003). Gemes et al. (2012) indicated that nerve injury
increases plasma membrane Ca2+-ATPase activity in sensory
neurons after spinal nerve ligation. It has also been shown
that an antagonist of all P2X receptors subtypes (TNP-ATP)
but not an antagonist specific to all subtypes excluding P2X4R
(PPADS) has a strong analgesic potency and ability to block
P2X4R upregulation on microglial cell cultures, pointing to
the crucial role of this specific P2X receptor subtype in pain
sensation (Tsuda et al., 2003). Tricarbonyldichlororuthenium (II)
dimer (CORM-2) has been reported to be an effective P2X4R
antagonist (Wilkinson and Kemp, 2011). We have also recently
reported that repeated intraperitoneal (ip.) administration
of CORM-2 significantly reduced mechanical and thermal
hypersensitivity in a rat model of neuropathy, and as preliminary
data, that repeated intrathecal (ith.) administration attenuate
thermal hypersensitivity. Moreover, a single ip. administration
of CORM-2 was able to enhance opioid analgesia (Jurga et al.,
2016a).
Despite the many studies on the topic, the involvement
and changes of the P2X4R under neuropathic pain remain
to be elucidated, but the P2X4R is known to be localized
mainly on microglia/macrophage cells. Therefore, we started
our experiments with an evaluation of the time course changes
in P2X4R levels in a rat neuropathic pain model [chronic
constriction injury of the sciatic nerve (CCI)]. Next, we decided
to use behavioral tests to examine if or how CORM-2 injected
intrathecally (ith.) can influence nociceptive transmission under
neuropathic pain. Moreover, using the Western blot technique,
we have measured the influence of CORM-2 on activated
glia and, in parallel, analyzed the protein levels of both the
pronociceptive (IL-1β, IL-18, IL-6) and antinociceptive (IL-
1Ra, IL-18BP, IL-10) factors in the dorsal horn of the lumbar
spinal cord and DRG in the CCI-exposed rats. Knowing that
the mature forms of IL-1β and IL-18 are cleaved by MMP-
9 (Schonbeck et al., 1998; Kawasaki et al., 2008) and/or
nucleotide-binding oligomerization domain, leucine rich repeat
and pyrin domain containing 3/caspase 1 (NLRP3/Casp-1)
inflammasome complex (Franchi et al., 2009), we decided
to examine the influence of CORM-2 on the activation of
those factors in the neuropathic pain model. Additionally,
we investigated the impact of this P2X4R antagonist on the
activation of the p38MAPK and ERK1/2 pathways and changes
in NFκB activation, which are known to be crucial for the
production of nociceptive factors during neuropathic pain
development (Tsuda et al., 2004; Hains and Waxman, 2006).
Recent publications report also contribution of phosphoinositide
3-kinase PI3K/Akt pathway in development of hypersensitivity
in different pain models (Tsuda et al., 2009; Pereira et al.,
2011; Xu et al., 2014), so we have included it in our
experiments. Moreover, we investigated how a single intrathecal
administration of CORM-2 would influence opioid (morphine
and buprenorphine) analgesia in a rat model of neuropathic
pain.
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MATERIALS AND METHODS
Animals
Male Wistar rats (250–300 g) from Charles River (Hamburg,
Germany) were housed in cages lined with sawdust under a
standard 12/12 h light/dark cycle (lights on at 06:00 a.m.)
with food and water available ad libitum. Only the minimal
essential number of animals was used, and all of the procedures
were performed according to the recommendations of IASP
(Zimmermann, 1983) and the NIH Guide for the Care and Use of
Laboratory Animals and this study was carried out in accordance
with the recommendations of local Ethics Committee (Krakow,
Poland).
Catheter Implantation
The intrathecal (ith.) injections were achieved through
implanting catheters according to the method of Yaksh and
Rudy (Yaksh and Rudy, 1976) under pentobarbital (60 mg/kg;
ip.) anesthesia, as was reported previously (Popiolek-Barczyk
et al., 2014). After implantation, the animals were allowed to
recover for a minimum of 1 week before the experiment.
Chronic Constriction Injury (CCI)
Chronic Constriction Injury was performed according to
Bennett and Xie (1988) under sodium pentobarbital anesthesia
(60 mg/kg; ip.). The procedure was described in detail in our
previous paper (Jurga et al., 2016a). As predicted, the CCI
surgery caused long-lasting neuropathic pain behaviors, such as
mechanical and thermal hypersensitivity, in all of the operated
rats.
Drug Administration
CORM-2 [tricarbonyldichlororuthenium (II) dimer, Sigma-
Aldrich, St. Louis, MO, USA] was administered repeatedly
once daily (20 µg/5 µl, ith.; dissolved in water for injection)
for 9 consecutive days. CORM-2 were delivered by producer
in sealed vial, which was opened shortly before experiments,
and then dissolved in freshly opened sterile water for injections
in autoclaved probe. The CCI surgery was defined as day 0;
CORM-2 was administered 16 h (day -1, late afternoon) and
1 h (day 0, early morning) before CCI and then daily from
day 1 to 7 after CCI (Scheme on Figure 2A). This method of
CORM-2 or vehicle administration was used throughout the
work and is referred to as “repeated administration” in the
text.
Morphine (2.5 µg/5 µl, ith.) or buprenorphine (2.5 µg/5 µl,
ith.) was administered as a single injection 2 h after CORM-2 on
day 7 after CCI, and the behavioral tests were conducted 30 min
later. The control groups received vehicle (water for injection)
according to the same schedule (Figure 8A).
Behavioral Tests
Two behavioral tests, von Frey’s and the cold plate, were
performed on day 7 after CCI, 2 h after the drug or vehicle
dose. The control groups received vehicle (water for injection)
according to the same schedule (Figure 2A). During the
behavioral tests on day 7, person responsible for substance
administration were passing animals from cages directly to
the von Frey apparatus cage, and then to the cold plate
box, where two different experimentators were performing
tests.
Von Frey’s Test
Mechanical hypersensitivity was measured in the rats subjected
to CCI using an automatic von Frey apparatus (Dynamic Plantar
Aesthesiometer, Ugo Basile, Italy). Rats were placed in plastic
cages with a wire net floor, and a von Frey’s filament was
applied to the midplantar surface of the CCI-exposed hind foot.
Measurements were taken automatically with a cut-off at 26 g
(Makuch et al., 2013).
Cold Plate Test
Thermal hypersensitivity was assessed using the Cold/Hot Plate
Analgesia Meter (Columbus Instruments, USA) as described
previously (Mika et al., 2007). The temperature of the cold
plate was maintained at 5◦C, and the cut-off latency of a single
measurement was 30 s. The rats were placed on the cold plate, and
the time until the hind foot was lifted was recorded. The injured
foot was the first to react in every case.
Western Blot Analysis
Rat ipsilateral dorsal lumbar (L4-L6) spinal cords and DRG
were collected immediately after decapitation on day 7 after
CCI, 6 h after the last drug administration. Tissue was
stored at −80◦C until processing, as described previously
(Rojewska et al., 2014). Blots were incubated overnight at 4◦C
with primary antibodies against the following proteins: IBA-
1 (rabbit anti-rat, 1:1000, Proteintech), GFAP (rabbit anti-rat,
1:10 000, Novus), P2X4R (rabbit anti-rat, 1:500, Alomone),
IL-1β (rabbit anti-rat, 1:1000, Abcam), IL-18 (rabbit anti-
rat, 1:1000, Abcam), IL-6 (rabbit anti-rat, 1:500, Invitrogen),
MMP-9 (rabbit anti-rat, 1:1000, EMD Millipore), TIMP-1
(rabbit anti-rat, 1:1000, Novus biologicals), IL-1Ra (rabbit
anti-rat, 1:1000, Abcam), IL-18BP (rabbit anti-rat, 1:1000,
Novus biologicals), IL-10 (rabbit anti-rat, 1:1000, Invitrogen),
p38MAPK (rabbit anti-rat, 1:1000, Cell Signaling), p-p38 MAPK
(rabbit anti-rat, 1:200, Cell Signaling), ERK1/2 (rabbit anti-
rat, 1:500, Cell Signaling), p-ERK1/2 (rabbit anti-rat, 1:500,
Cell Signaling), NFκB (rabbit anti-rat, 1:1000, Santa Cruz),
p-NFκB (rabbit anti-rat, 1:1000, Santa Cruz), PI3K (rabbit
anti-rat, 1:1000, Cell Signaling), Akt (rabbit anti-rat, 1:1000,
Cell Signaling), p-Akt (rabbit anti-rat, 1:1000, Cell Signaling),
NLRP3 (rabbit anti-rat, 1:500, Santa Cruz), Caspase-1 (rabbit
anti-rat, 1:500, Abcam), and GAPDH (mouse anti-rat, 1:5000,
Merck Millipore) as a loading control. Blots were incubated
for 1 h at RT with a corresponding secondary polyclonal
antibody conjugated to HRP (goat anti-rabbit IgG or horse anti-
mouse, 1:5000, Vector laboratories). Antibodies were diluted in
a Signal Boost Immunoreaction Enhancer Kit (Merck Millipore).
Immunocomplexes were detected using the ClarityTM Western
ECL Substrate (BioRad) and visualized using a Fujifilm LAS-4000
fluoroimager system.
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Data Analysis
Since, we have shown (Rojewska et al., 2015) that there are no
differences in neither nociceptive responses nor biochemical
analysis of protein levels between INTACT (not operated)
and SHAM (operated, without nerve injury) rats, we used
only INTACT animals for the experiments in the present
study. Behavioral data are presented as the mean ± SEM of
5–10 rats per group. Tests were performed on the following
rat groups: INTACT: healthy rats; V: vehicle-treated, CCI-
exposed; CORM-2: CORM-2-treated, CCI-exposed; V+M:
vehicle-treated with morphine administration, CCI-exposed;
V+B: vehicle-treated with buprenorphine administration,
CCI-exposed; CORM-2+M: CORM-2-treated with morphine
administration, CCI-exposed; and CORM-2+B: CORM-2-
treated with buprenorphine administration, CCI-exposed.
Inter-group differences were statistically evaluated by one-
way ANOVA followed by Bonferroni’s post hoc test using
GraphPad Prism 7 software. Significance was defined as
follows: ∗∗∗p < 0.001 compared to INTACT rats; #p < 0.05;
##p< 0.01; and ###p< 0.001 compared to V-treated CCI-exposed
rats; p < 0.01 and p < 0.001 compared to CORM-2-treated
CCI-exposed rats; $p < 0.05 and $$$p < 0.001 between the
V-CCI-opioid-treated groups and CORM-2-opioid-treated
groups. Protein analyses were performed using the Western blot
method. The analyses of the ipsilateral, dorsal lumbar (L4-L6)
spinal cord and DRG were performed in INTACT, V-treated
CCI-exposed group, and CORM-2-treated CCI-exposed group.
The results are presented as fold changes compared to the
INTACT group. The data are presented as the mean ± SEM and
represent the normalized averages derived from the analysis of
4–7 samples for each group. The analysis was performed with
the FUJIFILM Multi Gage V3.0 analysis program. Inter-group
differences were analyzed using one-way ANOVA followed by
Bonferroni’s multiple comparisons test using GraphPad Prism
7 software. ∗p < 0.05; ∗∗p < 0.01; and ∗∗∗p < 0.001 indicate a
significant difference compared to INTACT rats; and #p < 0.05;
##p < 0.01; and ###p < 0.001 indicate a significant difference
compared to V-treated CCI-exposed rats.
RESULTS
Changes in P2X4R, IBA-1 and GFAP
Protein Levels in the Spinal Cord and
DRG, as Measured on Days 2, 7, and 14
after CCI
Upregulation of P2X4R levels in the spinal cord was significant
at every time point (day 2: p < 0.01, day 7: p < 0.001, day
14: p < 0.05, Figure 1A), but there was no change in the DRG
(Figure 1B) after CCI comparing to INTACT group. We have
observed, in both the spinal cord and DRG, that IBA-1 protein
level was the most elevated on day 7 after CCI (p < 0.001,
Figures 1C,D) and slightly less but still significantly elevated on
day 14 after CCI (p< 0.05, Figures 1C,D) comparing to INTACT
group. GFAP started to upregulate in the spinal cord on day 7
after CCI (p < 0.05, Figure 1C) with the highest level on day 14
(p < 0.001, Figure 1E); in the DRG, this elevation started on day
2 after CCI (p < 0.01, Figure 1F) and lasted through days 7 and
14 (both p < 0.001, Figure 1F) comparing to healthy animals.
Effects of Chronic Intrathecal CORM-2
Administration on Hypersensitivity,
P2X4R, IBA-1, and GFAP Levels on Day 7
after CCI
Chronic constriction injury caused pain-related behavior and
repeated administration of CORM-2 (20 µg/5 µl, ith.),
an antagonist of P2X4R, significantly attenuated mechanical
(p < 0.01, Figure 2B) and thermal (p < 0.05, Figure 2C)
hypersensitivity as measured 2 h after the injection on day 7
(Figure 2A). However, CORM-2 did not influence the level of
P2X4R in the spinal cord (Figure 2D) or DRG (Figure 2E)
which was respectively: elevated and unchanged comparing to
INTACT group. Moreover, we observed that CORM-2 influenced
glia activation. CCI caused and elevation of glia markers levels in
spinal cord and DRG comparing to INTACT group and CORM-
2 diminished activation of IBA-1-positive cells in the spinal cord
(p < 0.001, Figure 2F) but not in the DRG (Figure 2G). The
protein level of GFAP was elevated in the V-treated CCI-exposed
group and was downregulated by CORM-2 in the spinal cord
(p < 0.05, Figure 2H) and DRG (p < 0.001, Figure 2I).
Effects of Chronic Intrathecal CORM-2
Administration on Protein Levels of
Pronociceptive Interleukins in the Spinal
Cord and DRG on Day 7 after CCI
Repeated CORM-2 administration (20 µg/5 µl, ith.) significantly
prevented activation of several pronociceptive factors during
neuropathic pain. We observed that the protein level of IL-1β
was significantly elevated after CCI comparing to INTACT group
and lower in the CORM-2-treated group than in the V-treated
CCI-exposed group in the spinal cord (p < 0.001, Figure 3A)
but the effect was not significant in the DRG (Figure 3B). IL-
18 protein levels were elevated after CCI comparing to INTACT
group and significantly downregulated after P2X4R antagonist
administration in both the spinal cord and DRG (p < 0.05,
Figures 3C,D). CORM-2 also prevented upregulation of IL-6
in the spinal cord (p < 0.01, Figure 3E) and DRG (p < 0.05,
Figure 3F).
Effects of Chronic Intrathecal CORM-2
Administration on MMP-9 and TIMP-1
Protein Levels in the Spinal Cord and
DRG on Day 7 after CCI
Significant upregulation of MMP-9 was detected in both the
spinal cord (p < 0.001, Figure 4A) and DRG (p < 0.001,
Figure 4B) in the V-treated CCI-exposed group comparing to
INTACT group, and this elevation was prevented by repeated
CORM-2 administration in both structures (in spinal cord:
p < 0.001, Figure 4A, and in DRG p < 0.01, Figure 4B).
TIMP-1 protein levels were not changed in either the V- nor
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FIGURE 1 | The Western blot analysis of the protein levels of the P2X4R (A,B), IBA-1 (C,D), and GFAP (E,F) in the ipsilateral dorsal lumbar spinal cord
(A,C,E) and dorsal root ganglia (DRG) (B,D,F) tissue on days 2, 7, and 14 after chronic constriction injury (CCI) in rats. The representative bands are shown below
each column of respective group on the graph and come from the same membrane photo. Samples from different groups were not next to each other so were cut
from different locations and set together. Data are presented as the mean ± SEM of 4–7 samples per group. Inter-group differences were analyzed using one-way
ANOVA followed by Bonferroni’s multiple comparisons test. ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001 compared to the INTACT group.
CORM-2-treated CCI-exposed group (Figures 4C,D) comparing
to INTACT group.
Effects of Chronic Intrathecal CORM-2
Administration on the Protein Levels of
Antinociceptive Factors in the Spinal
Cord and DRG on Day 7 after CCI
CORM-2 (20 µg/5 µl, ith.) administration led to the elevation
of antinociceptive IL-1Ra factor in the spinal cord (p < 0.05,
Figure 5A), and its level in both the spinal cord and DRG of
the V-treated CCI-exposed rats was not changed comparing to
INTACT group (Figures 5A,B). We did not observe any changes
in the levels of the other examined antinociceptive factors: IL-
18BP (Figures 5C,D) or IL-10 (Figures 5E,F) after CCI or
CORM-2-treatment comparing to INTACT group.
Effects of Chronic Intrathecal CORM-2
Administration on p38MAPK, ERK1/2
and NFκB Protein Levels in the Spinal
Cord and DRG on Day 7 after CCI
Repeated CORM-2 (20 µg/5 µl, ith.) administration prevented
p38MAPK activation in the DRG (p < 0.05, Figure 6B), with
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FIGURE 2 | Effects of repeated ith. CORM-2 administration (20 µg/5 µl, ith. 16 and 1 h before CCI and then once daily for 7 days) on the development
of mechanical (B; von Frey’s test) and thermal (C; cold plate test) hypersensitivity on day 7 after CCI as measured 2 h after the last drug administration (A). The
behavioral results are presented as the mean ± SEM (7–10 rats per group), and the horizontal dotted line shows the cut-off value (B: 26 g, C: 30 s). The Western
blot analysis (D–I) shows the influence of chronic ith. CORM-2 administration on protein levels of the P2X4R (D,E), IBA-1 (F,G) and GFAP (H,I) in the spinal cord
(D,F,H) and dorsal root ganglia (DRG) (E,G,I) on day 7 after CCI 6 h after the last drug administration. The representative bands are shown below each column of
respective group on the graph and come from the same membrane photo. Samples from different groups were not next to each other so were cut from different
locations and set together. Biochemical results are presented as the mean ± SEM (4–7 rats per group). The inter-group differences were analyzed using one-way
ANOVA with Bonferroni’s multiple comparisons test. ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001 compared to the INTACT animals; #p < 0.05; ##p < 0.01; and
###p < 0.001 compared to the V-treated CCI group.
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FIGURE 3 | The Western blot analysis shows the influence of repeated ith. CORM-2 administration on protein levels of IL-1β (A,B), IL-18 (C,D), and IL-6
(E,F) in the ipsilateral dorsal lumbar spinal cord (A,C,E) and dorsal root ganglia (DRG) (B,D,F) tissue on day 7 after chronic constriction injury (CCI) in rats 6 h after
the last drug administration. The representative bands are shown below each column of respective group on the graph and come from the same membrane photo.
Samples from different groups were not next to each other so were cut from different locations and set together. Data are presented as the mean ± SEM of 4–7
samples per group. Inter-group differences were analyzed using one-way ANOVA followed by Bonferroni’s multiple comparisons test. ∗p < 0.05, ∗∗p < 0.01, and
∗∗∗p < 0.001 compared to the INTACT group; #p < 0.05, ##p < 0.01; and ###p < 0.001 compared to the V-treated CCI group.
insignificant attenuation in the spinal cord (Figure 6A) compared
to that observed in V-treated CCI-exposed rats vs. INTACT
group. ERK1/2 was significantly upregulated after CCI in spinal
cord (p < 0.01, Figure 6C) and DRG (p < 0.001, Figure 6D)
comparing to healthy animals. Moreover, CORM-2 treatment
enhanced this elevation comparing to V-treated CCI-exposed
rats also in both spinal cord (p < 0.01, Figure 6C) and DRG
(p < 0.001, Figure 6D) NFκB levels of the CORM-2-treated
group remained on similar elevated level as that of the V-treated
CCI-exposed rats (p < 0.05, Figure 6E) when compared to that
of the INTACT group in the spinal cord, and in the DRG,
CORM-2 prevented the activation and upregulation of NFκB
when compared to the vehicle treatment in the CCI-exposed rats
(p < 0.05, Figure 6F).
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FIGURE 4 | The Western blot analysis shows the influence of repeated ith. CORM-2 administration on protein levels of MMP-9 (A,B) and TIMP-1 (C,D)
in the ipsilateral dorsal lumbar spinal cord (A,C) and dorsal root ganglia (DRG) (B,D) tissue on day 7 after chronic constriction injury (CCI) in rats 6 h after the last
drug administration. The representative bands are shown below each column of respective group on the graph and come from the same membrane photo. Samples
from different groups were not next to each other so were cut from different locations and set together. Data are presented as the mean ± SEM of 4–7 samples per
group. Inter-group differences were analyzed using one-way ANOVA followed by Bonferroni’s multiple comparisons test. ∗∗∗p < 0.001 compared to the INTACT
group; ##p < 0.01 and ###p < 0.001 compared to the V-treated CCI group.
Effects of Chronic Intrathecal CORM-2
Administration on PI3K and Akt Protein
Levels in the Spinal Cord and DRG on
Day 7 after CCI
Repeated CORM-2 (20 µg/5 µl, ith.) administration prevented
PI3K protein level upregulation in spinal cord (p < 0.001,
Figure 7A) and DRG (p < 0.05, Figure 7B) comparing to
V-treated CCI-exposed rats. Akt protein level was elevated in
spinal cord (p < 0.05, Figure 7C) but not in DRG (Figure 7D).
Those injections also prevented activation of Akt protein in spinal
cord (p < 0.05, Figure 7C) and lowered, unchanged after CCI,
its level in DRG comparing to V-treated CCI-exposed rats and
INTACT group (p < 0.05, Figure 7D).
Effect of a Single Intrathecal CORM-2
Administration on the Analgesic Effect of
Morphine and Buprenorphine on Day 7
after CCI
Single CORM-2 (20 µg/5 µl, ith.) administration had a similar
analgesic effect to chronic administration, as measured 2 h
after injection on day 7 after CCI with the von Frey’s test
(p < 0.001, Figure 8B) and cold plate test (p < 0.001,
Figure 8C). Single injection of both opioids produced analgesia
in the V-treated CCI-exposed group in both tests (V-treated
CCI-exposed group + morphine: p < 0.001, Figures 8B,C,
V-treated CCI-exposed group + buprenorphine: p < 0.001,
Figure 8B, C) 0.5 h after injection. Pretreatment with CORM-
2, 2 h before treatment with opioids significantly enhanced their
effectiveness in the von Frey’s (CORM-2-treated CCI-exposed
group+morphine: p< 0.001, Figure 8B, CORM-2-treated CCI-
exposed group + buprenorphine: p < 0.05, Figure 8B) and
cold plate (CORM-2-treated CCI-exposed group + morphine:
p < 0.05, Figure 8C, CORM-2-treated CCI-exposed group +
buprenorphine: p < 0.001, Figure 8C) tests.
DISCUSSION
Our studies provide new evidence that spinal microglial P2X4R
contribute to neuropathy development, since we observed
spinal upregulation of P2X4R levels in every measured time
point in parallel with activation of IBA-1-positive cells but no
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FIGURE 5 | The Western blot analysis shows the influence of repeated ith. CORM-2 administration on protein levels of IL-1Ra (A,B), IL-18BP (C,D),
and IL-10 (E,F) in the ipsilateral dorsal lumbar spinal cord (A,C,E) and dorsal root ganglia (DRG) (B,D,F) tissue on day 7 after chronic constriction injury (CCI) in rats
6 h after the last drug administration. The representative bands are shown below each column of respective group on the graph and come from the same membrane
photo. Samples from different groups were not next to each other so were cut from different locations and set together. Data are presented as the mean ± SEM of
4–7 samples per group. Inter-group differences were analyzed using one-way ANOVA followed by Bonferroni’s multiple comparisons test. ∗p < 0.05 compared to
the INTACT group; #p < 0.05 compared to the V-treated CCI group.
changes in the DRG. Here, we report that chronic, as well
as single pharmacological blockade of P2XR with CORM-2
(ith. administration, once daily for 9 days) diminished both
mechanical and thermal hypersensitivity in a rat model of
neuropathic pain on day 7 after CCI, which is a continuation of
our previously published results suggesting an important role of
P2X4R, however, we have measured only its influence on thermal
hypersensitivity at that time (Jurga et al., 2016a). Our results
indicate, for the first time, that blockade of P2X4R with chronic
ith. administration of CORM-2 prevents elevated levels (on day
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FIGURE 6 | The Western blot analysis shows the influence of repeated ith. CORM-2 administration on protein levels of p-p38 (A,B), p-ERK1/2 (C,D)
and p-NFκB (E,F) in the ipsilateral dorsal lumbar spinal cord (A,C,E) and dorsal root ganglia (DRG) (B,D,F) tissue on day 7 after chronic constriction injury (CCI) in
rats 6 h after the last drug administration. The representative bands are shown below each column of respective group on the graph and come from the same
membrane photo. Samples from different groups were not next to each other so were cut from different locations and set together. Data are presented as the
mean ± SEM of 4–7 samples per group. Inter-group differences were analyzed using one-way ANOVA followed by Bonferroni’s multiple comparisons test.
∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001 compared to the INTACT group; #p < 0.05, ##p < 0.01, and ###p < 0.001 compared to the V-treated CCI group.
7 after CCI) of glial markers (IBA-1 and GFAP) in the spinal
cord and/or DRG bringing it closer to the level observed in the
INTACT animals. A certain amount of pronociceptive factors,
e.g., cytokines, are known to be upregulated in neuropathic pain
and in the CCI model of neuropathy. We have examined the
protein levels of IL-1β, IL-18, and IL-6 released by activated
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FIGURE 7 | The Western blot analysis shows the influence of repeated ith. CORM-2 administration on protein levels of PI3K (A,B) and p-Akt (C,D) in
the ipsilateral dorsal lumbar spinal cord (A,C) and dorsal root ganglia (DRG) (B,D) tissue on day 7 after chronic constriction injury (CCI) in rats 6 h after the last drug
administration. The representative bands are shown below each column of respective group on the graph and come from the same membrane photo. Samples from
different groups were not next to each other so were cut from different locations and set together. Data are presented as the mean ± SEM of 4–7 samples per
group. Inter-group differences were analyzed using one-way ANOVA followed by Bonferroni’s multiple comparisons test. ∗p < 0.05 and ∗∗p < 0.01 compared to the
INTACT group; #p < 0.05 and ###p < 0.001 compared to the V-treated CCI group.
glial cells in the spinal cord and DRG. The results we report
suggest that blockade of microglial P2X4R transmission brings
those factors back to physiological levels. The antinociceptive
factors we examined (IL-1Ra, IL-18BP, and IL-10) remained at
the same level after CCI as those in INTACT animals; however,
we observed a strong upregulation of IL-1Ra in CORM-2-
treated CCI-exposed rats. The observation that even a single ith.
administration of CORM-2 has additive analgesic with morphine
and buprenorphine on day 7 after CCI supplements our previous
results on chronic ip. administration of CORM-2 and suggests
that P2X4R is an interesting molecular target for the treatment of
neuropathic pain.
As we have reported previously (Jurga et al., 2016a), activated
spinal microglia upregulation starts as early as day 2 after CCI,
with the biggest change on day 7, and lasts until day 14, when
it is still significant. Similarly, upregulation of microglia protein
markers was reported by others in the rat and mouse sciatic
nerve injury model on day 7 (Bishay et al., 2010) and day
14 (Kang et al., 2015). Astrocyte upregulation was reported in
CD1 mice in the CCI model on days 10 and 21 after surgery
(Chen et al., 2014), which, in combination with our results,
indicate that astroglia are activated later than microglia. In
relation to those results, we have observed spinal upregulation
of the P2X4R protein level parallel to microglial activation. This
suggests a relation between P2X4R and microglial activation in
neuropathy development in the Wistar rat CCI model, especially
considering that P2X4R was reported to co-localize only with
microglia and not with astrocytes or neurons in the central
nervous system (Tsuda et al., 2003). Results from the Wistar
rat SNL model showed upregulation in P2X4R protein levels on
days 1, 3, 7, and 14 (Tsuda et al., 2003) and in the Sprague-
Dawley rat CCI model on days 3, 7, and 14 (Chen X.M.
Frontiers in Pharmacology | www.frontiersin.org 11 February 2017 | Volume 8 | Article 48
fphar-08-00048 February 14, 2017 Time: 15:0 # 12
Jurga et al. P2X4R Role in Neuropathic Pain
FIGURE 8 | Effects of a single ith. CORM-2 injection (20 µg/5 µl, ith.)
on the (1) mechanical (B; von Frey’s test) and thermal (C; cold plate test)
hypersensitivity levels on day 7 after CCI as measured 2 h after drug
administration (A; scheme), (2) analgesic effect of a single administration of
morphine (M, 2.5 ug/5 µl, ith.) (B,C; V + M and CORM-2 + M), and (3)
analgesic effect of a single administration of buprenorphine (B, 2.5 ug/5 µl,
ith.) (B,C; V+ B and CORM-2 + B) as measured 0.5 h after opioids
administration (A; scheme). The behavioral results are presented as the
mean ± SEM (7–10 rats per group), and the horizontal dotted line shows the
value of the INTACT group. The inter-group differences were analyzed using
one-way ANOVA with Bonferroni’s multiple comparisons test. ###p < 0.001
compared to the V-treated CCI-exposed rats; p < 0.01 and p < 0.001
compared to the CORM-2-treated CCI-exposed rats; $p < 0.05 and
$$$p < 0.001 between the V-CCI-opioid treated groups and CORM-2-opioid
treated groups.
et al., 2015). DRG tissue analysis has not been reported yet;
however, here we show that the P2X4R level remains unchanged.
This supports the hypothesis on the contribution of microglial
P2X4R to neuropathy development because IBA-1-positive cells
responsible for the upregulation in the DRG are macrophages and
not microglia.
ATP, acting via P2 purinergic receptors, has been suggested to
mediate neuropathic pain development. The ATP-gated P2X4R is
SCHEME 1 | CORM-2 influences IBA-1- and GFAP-positive cells and
many nociceptive factors and signaling pathways as measured on day
7 after CCI. Our data strongly support the hypothesis that P2X4 receptors
play a significant role in neuropathy. In the nervous system, they are localized
on microglia/macrophages (Tsuda et al., 2003), and we have observed that
the elevation of levels of IBA-1- and GFAP-positive cells in the spinal cord and
DRG after chronic constriction injury (CCI) is prevented by preemptive
repeated administration of the P2X4 antagonist – CORM-2. Additionally,
pronociceptive factors released by those cells in neuropathy are regulated by
CORM-2 in a similar manner (IL-1β, IL-18, IL-6, MMP-9) in the spinal cord
and/or DRG. Additionally, P2X4R blockade also has the ability to enhance
production of spinal antinociceptive factor, IL-1Ra. We already know from
experiments using minocycline that the microglial p38MAPK pathway is
engaged in neuropathic pain (Jin et al., 2003), and here, we have shown for
the first time that P2X4R signaling also influences this pathway by preventing
the upregulation of p38 and enhancing ERK1/2 in the spinal cord and/or
DRG. In contrast, we did not detect any change in the NLRP3/Casp-1
inflammasome complex, which is in agreement with the literature
(Curto-Reyes et al., 2015). In summary, pharmacological blockade of P2X4
receptors diminished pain and increased the effectiveness of opioids in
neuropathy by influencing a variety of cell signaling pathways that are
implicated in nociception. The P2X4 receptor can be a potential target for a
new and more successful treatment for neuropathic pain. CORM-2,
CO releasing molecule 2; DRG, dorsal root ganglia; P2X4R, P2X4 receptor;
IBA-1, ionized calcium-binding adapter molecule 1; GFAP, glial fibrillary acidic
protein; IL, interleukin; IL-1Ra, interleukin 1 receptor antagonist;
IL-18BP, interleukin 18 binding protein; p38, p38 mitogen-activated protein
kinase; ERK1/2, extracellular signal-regulated kinase 1/2; NFκB,
(Continued)
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SCHEME 1 | Continued
nuclear factor-kappa β; NLRP3, nucleotide-binding oligomerization domain,
leucine rich repeat and pyrin domain containing 3; Casp-1, caspase 1; MMP-9,
matrix metalloproteinase 9; TIMP, tissue inhibitor of metalloproteinases.
Graphical data are presented as changes in the V-treated CCI-exposed
rat group compared to the INTACT group (black arrows or lines) and the
CORM-2-treated CCI-exposed rat group compared to the V-treated CCI-
exposed rat group (blue arrows or lines). The upright position of the
arrow symbolizes the upregulation of the corresponding factor, and the
downward position symbolizes its downregulation. The horizontal line
symbolizes no change between the above-mentioned groups.
considered to be involved in the modulation of spinal microglia
activity and peripheral macrophages and in the maintenance of
hypersensitivity caused by peripheral nerve injury (Trang and
Salter, 2012). Here, we report that pharmacological blockade of
P2X4R with CORM-2 (repeated and single ith. administration)
has the potential to diminish both mechanical and thermal
hypersensitivity in the rat CCI model of neuropathic pain as
measured on day 7 after the operation. This complements our
previously published results regarding ip. administration (Jurga
et al., 2016a) and supports the hypothesis on the important
role of P2X4R in neuropathic pain development. Moreover,
treatment with other available P2XR antagonists showed results
also favoring this supposition. For instance, experiments on mice
where the effects of two antagonists of P2XR were compared
(one selective to P2X4R and one to all other P2XRs) clearly
indicated that P2X4R is the most important among the P2X
receptor family (Tsuda et al., 2003). Until now, it has been
reported that ip. administration of CORM-2 has an analgesic
potency in a mouse SNL model (Liu et al., 2015), a mouse
inflammatory pain CFA model (Negrete et al., 2014) and in
a Sprague-Dawley rat CCI model 14 days after CCI (Chen
Y. et al., 2015). Blockade of receptors on microglia cells is
a promising target for neuropathic pain pharmacotherapy, as
reports regarding antagonism of Toll-like receptors 4 (Lewis
et al., 2013; Jurga et al., 2016b), histamine H4 receptors
(Medhurst et al., 2008; Hsieh et al., 2010; Dong et al., 2014),
or chemokine receptors (e.g., CCR5, CXCR4) (Bhangoo et al.,
2007; Hu et al., 2015; Bai et al., 2016; Kwiatkowski et al.,
2016; Luo et al., 2016; Piotrowska et al., 2016) are increasingly
common. We decided to investigate the changes caused by
P2X4R antagonism with CORM-2 (repeated ith. administration)
in some pathways related to the activity of those receptors whose
role in neuropathic pain has already been proposed. First, we
examined the p38MAPK pathway. It is known that p38MAPK
is activated in microglia/macrophages cells in neuropathic pain
models (Jin et al., 2003; Tsuda et al., 2004). Interestingly, it is
reported that TNP-ATP, a specific P2X4R antagonist, has the
ability to downregulate this receptor in microglial cultures when
its level was previously elevated after ATP stimulation (Tsuda
et al., 2003). This draws attention to the possible relationship
between activation of P2X4R and the p38MAPK pathway, which
leads to the enhanced production of pronociceptive factors,
including NO and cytokines (DeLeo and Yezierski, 2001),
and to the activation of transcription factors responsible for
regulation of genes involved in nociception (Potucek et al.,
2006). Pharmacological inhibition of p38MAPK and activation
of microglia/macrophages has analgesic potency in neuropathic
pain models, as has been reported with minocycline (Tikka
et al., 2001; Popiolek-Barczyk et al., 2015) or SB203580 (Tsuda
et al., 2004) treatment. In our experiments, we observed a
downregulation of p38MAPK by CORM-2 in the DRG but not
in the spinal cord in the neuropathic pain model. Another
member of the MAPK family that we examined was ERK1/2,
which is strongly activated within neurons and glia during
neuropathic pain. Our results are in agreement with previously
published results that show that ERK1/2 phosphorylation is
increased on day 7 after CCI (Rojewska et al., 2015), which is
correlated with enhanced glial cell activation (Popiolek-Barczyk
et al., 2015). Previously, published results suggested that ERK1/2
is essential for the intracellular signaling that leads to the
production of various nociceptive factors, including cytokines,
that participate in the intensification of the neuropathic pain
sensations (Popiolek-Barczyk et al., 2015; Rojewska et al., 2015).
In our experiments, we measured the spinal upregulation of
p-ERK1/2 by CORM-2 in the neuropathic pain model and, in
parallel, the level of antinociceptive IL-1Ra. However, whether
this or other (unknown yet) relationship is important for the
observed effect requires clarification and further studies. In the
DRG we did not observe any impact of CORM-2 administration
on IL-1Ra levels, which can be explain by ith. administration.
Excessive production of the above-mentioned pronociceptive
factors, e.g., interleukins, are known to be upregulated in
neuropathy models (Verri et al., 2007; Rojewska et al., 2014, 2015;
Popiolek-Barczyk et al., 2015). IL-1β and IL-18 promotes pain
behavior development when injected intrathecally (Malcangio
et al., 1996; Miyoshi et al., 2008). IL-1β, IL-18 and IL-6 are
spinally upregulated in neuropathic pain models, including our
reports (Okamoto et al., 2001; Pilat et al., 2015, 2016; Rojewska
et al., 2016). Interestingly, the results we observed suggest that
TABLE 1 | The Western blot analysis showed the influence of repeated ith. CORM-2 administration on protein levels of Nucleotide-binding
oligomerization domain, Leucine-rich Repeat and Pyrin domain containing 3 (NLRP3) and Caspase-1 (Casp-1) in the ipsilateral dorsal lumbar spinal cord
and dorsal root ganglia (DRG) tissue on day 7 after chronic constriction injury (CCI) in rats 6 h after the last ith. CORM-2 administration.
Spinal cord DRG
INTACT V CCI CORM-2 CCI INTACT V CCI CORM-2 CCI
NLRP3 1.00 ± 0.03 1.00 ± 0.11 0.96 ± 0.07 1.00 ± 0.06 1.16 ± 0.01 1.15 ± 0.05
Casp-1 1.00 ± 0.03 1.19 ± 0.10 1.18 ± 0.11 1.00 ± 0.03 0.94 ± 0.04 0.97 ± 0.06
Data are presented as the mean ± SEM of 4–7 samples per group. Inter-group differences were analyzed using one-way ANOVA followed by Bonferroni’s multiple
comparisons test.
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blockade of microglial P2X4R transmission restores the elevated
levels of pronociceptive factors in neuropathy. Moreover, we have
shown that the MMP-9 level is elevated in rats after CCI in the
spinal cord and DRG (Schonbeck et al., 1998; Kawasaki et al.,
2008; Rojewska et al., 2014), but here, we are the first to show
that preemptive and repeated P2X4R blockade has the ability to
prevent this upregulation. This observation is important, since
Kawasaki et al. (2008) has proven that MMP-9 produced in the
injured DRG neurons serves as one of the triggers for spinal
microglia activation and neuropathic pain development and that
MMP-9-induced pathophysiology involves IL-1β cleavage and
microglia p38MAPK activation. These observations, along with
the identical regulation of pronociceptive spinal IL-1β in the
spinal cord, are extremely important. Our results are also in
agreement with Vaccari et al. (2012), who reported a decrease in
IL-1β release in P2X4R−/− mice after spinal cord injury, which
resulted in an improvement in the functional outcome. The
results of our studies provided evidence that blocking P2X4Rs
prevents microglial activation and, consequently, the release of
pronociceptive molecules. It is claimed that under neuropathic
pain, the physiological balance between pronociceptive and
antinociceptive factors is disturbed (Mika et al., 2008; Rojewska
et al., 2014, 2015). The corresponding antinociceptive factors that
we examined were expressed at the same level as those in the
INTACT group on day 7 after CCI. However, we observed a
strong upregulation of spinal IL-1Ra in CORM-2-treated CCI-
exposed rats. IL-1Ra is a member of the IL-1 family that binds to
IL-1 receptors but does not induce any intracellular response. The
IL-1Ra blocks the pronociceptive effects of IL-1β and therefore
has a strong analgesic effect under neuropathy (Hook et al.,
2011; Pilat et al., 2015). Chronic ith. administration of CORM-
2 inhibited microglial activation in neuropathy and enhanced
the level of IL-1Ra, an important antinociceptive factor. We also
examined the level of IL-18BP, which is known to inactivate
pronociceptive IL-18 (Kim et al., 2000; Pilat et al., 2016);
however CORM-2 administration did not influence its level.
Another important antinociceptive cytokine is IL-10 (Bluthé
et al., 1999; Heyen et al., 2000), but like IL-18BP, its level was not
regulated by CORM-2 administration. This may suggest that the
mechanism of IL-1Ra activation relies on the P2X4R-mediated
pathway and that this molecule, along with pronociceptive IL-
1β (IL-1Ra blocks its activation), plays a key role in neuropathy
development.
ATP, an endogenous agonist of purinergic receptors, has
the ability to activate p38MAPK with the release of cytokines
and other microglial factors engaged in nociception. According
to the literature, the second pathway important to investigate
was the NLRP3/Caspase-1 inflammasome, because this complex
is responsible for the cleavage of the preforms of IL-1β
and IL-18 into active molecules (Rathinam et al., 2012).
Moreover, Jiang L. et al. (2016) reported that in mice,
CORM-2 administration in an acute lung injury model
downregulates the level of elevated NLRP3/Caspase-1 in the lung
bronchoalveolar lavage fluid, suggesting engagement of P2X4R
in the activation of the inflammasome. However, we did not
observe activation of this complex in the CCI model, which
we found was in agreement with the studies of Curto-Reyes
et al. (2015) who recently reported that pain development is
not dependent on NLRP3/Caspase-1 in a mouse SNL model
(Table 1).
The recent literature data suggest that activation of PI3K/Akt
pathway is strongly involved in release of interleukins and other
microglial factors involved in nociception, which is in agreement
with our results showing the activation of PI3K/Akt pathway
after CCI in rats on day 7. Similarly, it has been presented,
that this pathway is upregulated undergo activation, e.g., in
Oxaliplatin chemotherapy-induced neuropathic pain in mice
(Jiang S.P. et al., 2016). Significant upregulation of p-Akt in
DRG neurons was also reported after L5 spinal nerve ligation
rat model, with attenuation of behavioral pain symptoms after
PI3K inhibitors administration (wortmannin or LY294002) (Xu
et al., 2014). It was proven that AS605240 (PI3K inhibitor)
produced a significant relief in tripsine-induced nociception in
mice (Pereira et al., 2011). Not to neglect remains also the
fact, that administration of PI3K inhibitor (LY294002) into
primary microglial culture suppresses the P2X4R upregulation
after fibronectin introduction (Tsuda et al., 2009). Moreover,
it has been shown, using chemoattractant protein-1 (MCP1)-
mediated bone cancer pain model, that there is a significant
dependence between PI3K/Akt and microglia activation (Jin
et al., 2015). Here we show that repeated ith. administration
of CORM-2 lowers levels of both PI3K and p-Akt protein in
spinal cord and DRG suggesting its significant contribution to
P2X4R-mediated pain development.
The P2X4R antagonist has potency to not only diminish
mechanical and thermal hypersensitivity in a rat CCI model
of neuropathic pain but also enhance opioid analgesia. The
observation that a single ith. administration of CORM-2
enhances the analgesic effects of single-injected morphine and
buprenorphine on day 7 after CCI supplements our previous
results obtained after ip. administration of CORM-2 (Jurga
et al., 2016a). It is known that opioids, commonly used in
the clinic for inflammatory or acute pain therapy, lose their
efficacy in neuropathic pain. This may be connected with the
development of tolerance (Narita et al., 2008), downregulation
of opioid receptors (Mika et al., 2014) and activation of
p38MAPK along with the enhanced release of pronociceptive
factors (Raghavendra et al., 2004; Hutchinson et al., 2008a).
Inhibition of microglia activation and secretion of nociceptive
factors by certain pharmacological tools has been shown to
improve opioid analgesia, for example treatment with an
inhibitor of microglia – minocycline (Hutchinson et al., 2008b),
pronociceptive interleukin – propentofylline (Miki and Miki,
1991; Raghavendra et al., 2004) or p38MAPK inhibitor -
SB203580 (Cui et al., 2006). Moreover, in 2015 authors suggested
that the activation of PI3K/Akt pathway can influence the opioid
effectiveness, which stays in agreement with our pharmacological
results showing both morphine and buprenorphine analgesic
properties are enhanced by CORM-2, inhibitor of this pathway
(Lutz et al., 2015). According to those results, pharmacological
blockade of P2X4R may be a promising target for neuropathic
pain therapy because, as we report here, CORM-2 administration
leads to the attenuation of pronociceptive cytokine levels and
significant analgesia with the ability to enhance both morphine
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and buprenorphine effectiveness. Together, this indicates that
P2X4R may play an important role in nociception and opioid
effectiveness in neuropathic pain and is, therefore, a promising
target for effective therapy construction.
CONCLUSION
Our results support the hypothesis that spinal microglial P2X4R
contribute to neuropathy development, since we have observed
spinal upregulation of P2X4R levels at every time point in
parallel with activation of IBA-1-positive and GFAP-positive
cells. Our results confirmed that preemptive and repeated
pharmacological spinal blockade of P2X4R can attenuate pain
as well as improve opioid analgesia on day 7 after CCI.
Interestingly, we observed (Scheme 1) that CORM-2 inhibited
pronociceptive factors (IL-1β, IL-18, IL-6) in the spinal cord
and/or DRG along with the MMP-9 factor, which is a well-
known contributor to IL-1β activation and spinal microglia
activation. Moreover, CORM-2 treatment led to the elevation
of antinociceptive IL-1Ra, a molecule whose action opposes
that of pronociceptive IL-1β. With strong support from our
results summarized in Scheme 1, we are proposing a hypothesis
that MMP-9, p38MAPK, ERK1/2 and PI3K/Akt, not TIMP-1
and the NLRP3/Caspase-1 inflammasome complex, are involved
in the analgesic effects of CORM-2 in rat neuropathic pain.
Taking this into consideration, it is highly probable that
microglial P2X4R may be involved in nerve-injury caused
nociception because our results showed that treatment with
CORM-2 restores the physiological level of pronociceptive
factors in neuropathy and attenuates pain. This suggests that
P2XR is a promising target for pharmacomodulation in future
trials.
ETHICS STATEMENT
Only the minimal essential number of animals was used,
and all of the procedures were performed according to the
recommendations of IASP (Zimmermann, 1983) and the NIH
Guide for the Care and Use of Laboratory Animals. This study
was carried out in accordance with the recommendations of local
Ethics Committee (Krakow, Poland), permission number: 1055.
AUTHOR CONTRIBUTIONS
AJ, AP, WM, BP, and JM performed the experiments, AJ and
JM designed the study, AJ, AP, JM analyzed and interpreted the
results, AJ, AP, WM, BP, and JM drafted the manuscript and
accepted the finalized version.
FUNDING
This work was supported by the National Science Center, Poland,
via grant Harmonia 5 2013/10/M/NZ4/00261 and by statutory
funds from the Institute of Pharmacology PAS, Department of
Pain Pharmacology.
ACKNOWLEDGMENTS
AJ and AP are holders of KNOW scholarships sponsored by the
Ministry of Science and Higher Education, Republic of Poland.
The manuscript was edited for proper English language by
American Journal Experts.
REFERENCES
Bai, L., Wang, X., Li, Z., Kong, C., Zhao, Y., Qian, J. L., et al. (2016). Upregulation
of chemokine CXCL12 in the dorsal root ganglia and spinal cord contributes
to the development and maintenance of neuropathic pain following spared
nerve injury in rats. Neurosci. Bull. 32, 27–40. doi: 10.1007/s12264-015-
0007-4
Beggs, S., and Salter, M. W. (2013). The known knowns of microglia-neuronal
signalling in neuropathic pain. Neurosci. Lett. 557, 37–42. doi: 10.1016/j.neulet.
2013.08.037
Bennett, G. J., and Xie, Y.-K. (1988). A peripheral mononeuropathy in rat that
produces disorders of pain sensation like those seen in man. Pain 33, 87–107.
doi: 10.1016/0304-3959(88)90209-6
Bhangoo, S. K., Ren, D., Miller, R. J., Chan, D. M., Ripsch, M. S., Weiss, C., et al.
(2007). CXCR4 chemokine receptor signaling mediates pain hypersensitivity
in association with antiretroviral toxic neuropathy. Brain Behav. Immun. 21,
581–591. doi: 10.1016/j.bbi.2006.12.003
Bishay, P., Schmidt, H., Marian, C., Häussler, A., Wijnvoord, N., Ziebell, S.,
et al. (2010). R-flurbiprofen reduces neuropathic pain in rodents by restoring
endogenous cannabinoids. PLoS ONE 5:e10628. doi: 10.1371/journal.pone.
0010628
Bluthé, R. M., Castanon, N., Pousset, F., Bristow, A., Ball, C., Lestage, J., et al.
(1999). Central injection of IL-10 antagonizes the behavioural effects of
lipopolysaccharide in rats. Psychoneuroendocrinology 24, 301–311. doi: 10.1016/
S0306-4530(98)00077-8
Burke, D., Fullen, B. M., Stokes, D., and Lennon, O. (2017). Neuropathic pain
prevalence following spinal cord injury: a systematic review and meta-analysis.
Eur. J. Pain 21, 29–44. doi: 10.1002/ejp.905
Burma, N. E., Leduc-Pessah, H., Fan, C. Y., and Trang, T. (2016). Animal models of
chronic pain: advances and challenges for clinical translation. J. Neurosci. Res.
doi: 10.1002/jnr.23768 [Epub ahead of print],
Chen, G., Park, C. K., Xie, R. G., Berta, T., Nedergaard, M., and Ji, R. R.
(2014). Connexin-43 induces chemokine release from spinal cord astrocytes
to maintain late-phase neuropathic pain in mice. Brain 137, 2193–2209. doi:
10.1093/brain/awu140
Chen, X. M., Xu, J., Song, J. G., Zheng, B. J., and Wang, X. R.
(2015). Electroacupuncture inhibits excessive interferon-γ evoked up-
regulation of P2X4 receptor in spinal microglia in a CCI rat model
for neuropathic pain. Br. J. Anaesth. 114, 150–157. doi: 10.1093/bja/
aeu199
Chen, Y., Chen, H., Xie, K., Liu, L., Li, Y., Yu, Y., et al. (2015). H2 treatment
attenuated pain behavior and cytokine release through the HO-1/CO pathway
in a rat model of neuropathic pain. Inflammation 38, 1835–1846. doi: 10.1007/
s10753-015-0161-x
Cockayne, D. A., Hamilton, S. G., Zhu, Q. M., Dunn, P. M., Zhong, Y.,
Novakovic, S., et al. (2000). Urinary bladder hyporeflexia and reduced pain-
related behaviour in P2X3-deficient mice. Nature 407, 1011–1015. doi: 10.1038/
35039519
Cui, Y., Chen, Y., Zhi, J. L., Guo, R. X., Feng, J. Q., and Chen, P. X. (2006).
Activation of p38 mitogen-activated protein kinase in spinal microglia mediates
Frontiers in Pharmacology | www.frontiersin.org 15 February 2017 | Volume 8 | Article 48
fphar-08-00048 February 14, 2017 Time: 15:0 # 16
Jurga et al. P2X4R Role in Neuropathic Pain
morphine antinociceptive tolerance. Brain Res. 1069, 235–243. doi: 10.1016/j.
brainres.2005.11.066
Cui, Y., Liao, X.-X., Liu, W., Guo, R.-X., Wu, Z.-Z., Zhao, C.-M., et al. (2008).
A novel role of minocycline: attenuating morphine antinociceptive tolerance by
inhibition of p38 MAPK in the activated spinal microglia. Brain. Behav. Immun.
22, 114–123. doi: 10.1016/j.bbi.2007.07.014
Curto-Reyes, V., Kirschmann, G., Pertin, M., Drexler, S. K., Decosterd, I.,
and Suter, M. R. (2015). Neuropathic pain phenotype does not involve
the NLRP3 inflammasome and its end product interleukin-1?? in the Mice
spared nerve injury model. PLoS ONE 10:e0133707. doi: 10.1371/journal.pone.
0133707
DeLeo, J. A., and Yezierski, R. P. (2001). The role of neuroinflammation and
neuroimmune activation in persistent pain. Pain 90, 1–6. doi: 10.1016/S0304-
3959(00)00490-5
Dong, H., Zhang, W., Zeng, X., Hu, G., Zhang, H., He, S., et al. (2014). Histamine
induces upregulated expression of histamine receptors and increases release
of inflammatory mediators from microglia. Mol. Neurobiol. 49, 1487–1500.
doi: 10.1007/s12035-014-8697-6
Franchi, L., Eigenbrod, T., Muñoz-Planillo, R., and Nuñez, G. (2009). The
inflammasome: a caspase-1-activation platform that regulates immune
responses and disease pathogenesis. Nat. Immunol. 10, 241–247. doi: 10.1038/
ni.1703
Furlan, A. D., Sandoval, J. A., Mailis-Gagnon, A., and Tunks, E. (2006). Opioids
for chronic noncancer pain: a meta-analysis of effectiveness and side effects
(Structured abstract). Can. Med. Assoc. J. 174, 1589–1594. doi: 10.1503/cmaj.
051528
Gemes, G., Oyster, K. D., Pan, B., Wu, H.-E., Bangaru, M. L. Y., Tang, Q.,
et al. (2012). Painful nerve injury increases plasma membrane Ca2+-ATPase
activity in axotomized sensory neurons. Mol. Pain 8:46. doi: 10.1186/1744-
8069-8-46
Grygorowicz, T., Wełniak-Kamin´ska, M., and Struz˙yn´ska, L. (2016). Early P2X7R-
related astrogliosis in autoimmune encephalomyelitis. Mol. Cell. Neurosci. 74,
1–9. doi: 10.1016/j.mcn.2016.02.003
Hains, B. C., and Waxman, S. G. (2006). Activated microglia contribute to the
maintenance of chronic pain after spinal cord injury. J. Neurosci. 26, 4308–4317.
doi: 10.1523/JNEUROSCI.0003-06.2006
Heyen, J. R., Ye, S., Finck, B. N., and Johnson, R. W. (2000). Interleukin
(IL)-10 inhibits IL-6 production in microglia by preventing activation
of NF-κB. Mol. Brain Res. 77, 138–147. doi: 10.1016/S0169-328X(00)
00042-5
Hook, M. A., Washburn, S. N., Moreno, G., Woller, S. A., Puga, D., Lee, K. H., et al.
(2011). An IL-1 receptor antagonist blocks a morphine-induced attenuation of
locomotor recovery after spinal cord injury. Brain Behav. Immun. 25, 349–359.
doi: 10.1016/j.bbi.2010.10.018
Hsieh, G. C., Honore, P., Pai, M., Wensink, E. J., Chandran, P., Salyers, A. K.,
et al. (2010). Antinociceptive effects of histamine H3 receptor antagonist
in the preclinical models of pain in rats and the involvement of central
noradrenergic systems. Brain Res. 1354, 74–84. doi: 10.1016/j.brainres.2010.
07.083
Hu, X. M., Liu, Y. N., Zhang, H. L., Cao, S. B., Zhang, T., Chen, L. P., et al.
(2015). CXCL12/CXCR4 chemokine signaling in spinal glia induces pain
hypersensitivity through MAPKs-mediated neuroinflammation in bone cancer
rats. J. Neurochem. 132, 452–463. doi: 10.1111/jnc.12985
Hutchinson, M. R., Coats, B. D., Lewis, S. S., Zhang, Y., Sprunger, D. B., Rezvani, N.,
et al. (2008a). Proinflammatory cytokines oppose opioid-induced acute and
chronic analgesia. Brain. Behav. Immun. 22, 1178–1189. doi: 10.1016/j.bbi.2008.
05.004
Hutchinson, M. R., Northcutt, A. L., Chao, L. W., Kearney, J. J., Zhang, Y.,
Berkelhammer, D. L., et al. (2008b). Minocycline suppresses morphine-induced
respiratory depression, suppresses morphine-induced reward, and enhances
systemic morphine-induced analgesia. Brain Behav. Immun. 22, 1248–1256.
doi: 10.1016/j.bbi.2008.07.008
Irnich, D., Tracey, D. J., Polten, J., Burgstahler, R., and Grafe, P. (2002).
ATP stimulates peripheral axons in human, rat and mouse – Differential
involvement of A2B adenosine and P2X purinergic receptors. Neuroscience 110,
123–129. doi: 10.1016/S0306-4522(01)00556-5
Jiang, L., Fei, D., Gong, R., Yang, W., Yu, W., Pan, S., et al. (2016).
CORM-2 inhibits TXNIP/NLRP3 inflammasome pathway in LPS-induced
acute lung injury. Inflamm. Res. 65, 1–11. doi: 10.1007/s00011-016-
0973-7
Jiang, S. P., Zhang, Z. D., Kang, L. M., Wang, Q. H., Zhang, L., and Chen,
H. P. (2016). Celecoxib reverts oxaliplatin-induced neuropathic pain through
inhibiting PI3K/Akt2 pathway in the mouse dorsal root ganglion. Exp. Neurol.
275, 11–16. doi: 10.1016/j.expneurol.2015.11.001
Jin, D., Yang, J. P., Hu, J. H., Wang, L. N., and Zuo, J. L. (2015). MCP-1 stimulates
spinal microglia via PI3K/Akt pathway in bone cancer pain. Brain Res. 1599,
158–167. doi: 10.1016/j.brainres.2014.12.043
Jin, S.-X., Zhuang, Z.-Y., Woolf, C. J., and Ji, R.-R. (2003). p38 mitogen-
activated protein kinase is activated after a spinal nerve ligation in spinal cord
microglia and dorsal root ganglion neurons and contributes to the generation
of neuropathic pain. J. Neurosci. 23, 4017–4022.
Jurga, A. M., Piotrowska, A., Starnowska, J., Rojewska, E., Makuch, W.,
and Mika, J. (2016a). Treatment with a carbon monoxide-releasing
molecule (CORM-2) inhibits neuropathic pain and enhances opioid
effectiveness in rats. Pharmacol. Rep. 68, 206–213. doi: 10.1016/j.pharep.2015.
08.016
Jurga, A. M., Rojewska, E., Piotrowska, A., Makuch, W., Pilat, D., Przewlocka, B.,
et al. (2016b). Blockade of toll-like receptors (TLR2, TLR4) attenuates pain and
potentiates buprenorphine analgesia in a rat neuropathic pain model. Neural
Plast. 2016, 1–12. doi: 10.1155/2016/5238730
Kang, S.-Y., Roh, D.-H., Choi, J.-W., Ryu, Y., and Lee, J.-H. (2015). Repetitive
treatment with diluted bee venom attenuates the induction of below-level
neuropathic pain behaviors in a rat spinal cord injury model. Toxins (Basel)
7, 2571–2585. doi: 10.3390/toxins7072571
Kawasaki, Y., Zhen-Zhong, X., Xiaoying, W., Park, J.-Y., Zhuang, Z.-Y., Tan, P.-H.,
et al. (2008). Distinct roles of matrix metalloproteases in the early- and late-
phase development of neuropathic pain. Nat. Med. 14, 331–336. doi: 10.1038/
nm1723
Kim, S. H., Eisenstein, M., Reznikov, L., Fantuzzi, G., Novick, D., Rubinstein, M.,
et al. (2000). Structural requirements of six naturally occurring isoforms of
the IL-18 binding protein to inhibit IL-18. Proc. Natl. Acad. Sci. U.S.A. 97,
1190–1195. doi: 10.1073/pnas.97.3.1190
Kwiatkowski, K., Piotrowska, A., Rojewska, E., Makuch, W., Jurga, A.,
Slusarczyk, J., et al. (2016). Beneficial properties of maraviroc on
neuropathic pain development and opioid effectiveness in rats. Prog.
Neuropsychopharmacol. Biol. Psychiatry 64, 68–78. doi: 10.1016/j.pnpbp.
2015.07.005
Lazarowski, E. R., Boucher, R. C., and Harden, T. K. (2003). Mechanisms of
release of nucleotides and integration of their action as P2X- and P2Y-receptor
activating molecules. Mol. Pharmacol. 64, 785–795. doi: 10.1124/mol.64.
4.785
Ledeboer, A., Jekich, B. M., Sloane, E. M., Mahoney, J. H., Langer, S. J., Milligan,
E. D., et al. (2007). Intrathecal interleukin-10 gene therapy attenuates paclitaxel-
induced mechanical allodynia and proinflammatory cytokine expression in
dorsal root ganglia in rats. Brain Behav. Immun. 21, 686–698. doi: 10.1016/j.
bbi.2006.10.012
Lewis, S. S., Hutchinson, M. R., Zhang, Y., Hund, D. K., Maier, S. F., Rice, K. C.,
et al. (2013). Glucuronic acid and the ethanol metabolite ethyl-glucuronide
cause toll-like receptor 4 activation and enhanced pain. Brain. Behav. Immun.
30, 24–32. doi: 10.1016/j.bbi.2013.01.005
Liu, X., Zhang, Z., Cheng, Z., Zhang, J., Xu, S., Liu, H., et al. (2015). Spinal
heme oxygenase-1 (HO-1) exerts antinociceptive effects against neuropathic
pain in a mouse model of L5 spinal nerve ligation. Pain Med. 17, 220–229.
doi: 10.1111/pme.12906
Luo, X., Tai, W. L., Sun, L., Pan, Z., Xia, Z., Chung, S. K., et al. (2016).
Crosstalk between astrocytic CXCL12 and microglial CXCR4 contributes to
the development of neuropathic pain. Mol. Pain 12:1744806916636385. doi:
10.1177/1744806916636385
Lutz, B. M., Nia, S., Xiong, M., Tao, Y.-X., and Bekker, A. (2015). mTOR, a new
potential target for chronic pain and opioid-induced tolerance and hyperalgesia.
Mol. Pain 11:32. doi: 10.1186/s12990-015-0030-5
Makuch, W., Mika, J., Rojewska, E., Zychowska, M., and Przewlocka, B. (2013).
Effects of selective and non-selective inhibitors of nitric oxide synthase on
morphine- and endomorphin-1-induced analgesia in acute and neuropathic
pain in rats. Neuropharmacology 75, 445–457. doi: 10.1016/j.neuropharm.2013.
08.031
Frontiers in Pharmacology | www.frontiersin.org 16 February 2017 | Volume 8 | Article 48
fphar-08-00048 February 14, 2017 Time: 15:0 # 17
Jurga et al. P2X4R Role in Neuropathic Pain
Malcangio, M., Bowery, N., Flower, R., and Perretti, M. (1996). Effect of
interleukin-1 beta on the release of substance P from rat isolated spinal cord.
Eur. J. Pharmacol. 299, 113–118. doi: 10.1016/0014-2999(95)00845-4
Medhurst, S. J., Collins, S. D., Billinton, A., Bingham, S., Dalziel, R. G., Brass, A.,
et al. (2008). Novel histamine H3 receptor antagonists GSK189254 and
GSK334429 are efficacious in surgically-induced and virally-induced rat models
of neuropathic pain. Pain 138, 61–69. doi: 10.1016/j.pain.2007.11.006
Mika, J., Korostynski, M., Kaminska, D., Wawrzczak-Bargiela, A., Osikowicz, M.,
Makuch, W., et al. (2008). Interleukin-1 alpha has antiallodynic and
antihyperalgesic activities in a rat neuropathic pain model. Pain 138, 587–597.
doi: 10.1016/j.pain.2008.02.015
Mika, J., Osikowicz, M., Makuch, W., and Przewlocka, B. (2007). Minocycline and
pentoxifylline attenuate allodynia and hyperalgesia and potentiate the effects of
morphine in rat and mouse models of neuropathic pain. Eur. J. Pharmacol. 560,
142–149. doi: 10.1016/j.ejphar.2007.01.013
Mika, J., Popiolek-Barczyk, K., Rojewska, E., Makuch, W., Starowicz, K., and
Przewlocka, B. (2014). Delta-opioid receptor analgesia is independent of
microglial activation in a rat model of neuropathic pain. PLoS ONE 9:e104420.
doi: 10.1371/journal.pone.0104420
Mika, J., Zychowska, M., Popiolek-Barczyk, K., Rojewska, E., and Przewlocka, B.
(2013). Importance of glial activation in neuropathic pain. Eur. J. Pharmacol.
716, 106–119. doi: 10.1016/j.ejphar.2013.01.072
Miki, S., and Miki, Y. (1991). Differential effects of propentofylline on the
production of cytokines by peripheral blood mononuclear cells in vitro. Clin.
Ther. 13, 747–753.
Miyoshi, K., Obata, K., Kondo, T., Okamura, H., and Noguchi, K. (2008).
Interleukin-18-mediated microglia/astrocyte interaction in the spinal cord
enhances neuropathic pain processing after nerve injury. J. Neurosci. 28, 12775–
12787. doi: 10.1523/JNEUROSCI.3512-08.2008
Narita, M., Nakamura, A., Ozaki, M., Imai, S., Miyoshi, K., Suzuki, M., et al. (2008).
Comparative pharmacological profiles of morphine and oxycodone under a
neuropathic pain-like state in mice: evidence for less sensitivity to morphine.
Neuropsychopharmacology 33, 1097–1112. doi: 10.1038/sj.npp.1301471
Negrete, R., Hervera, A., Leánez, S., and Pol, O. (2014). Treatment with a carbon
monoxide-releasing molecule inhibits chronic inflammatory pain in mice:
nitric oxide contribution. Psychopharmacology (Berl.) 231, 853–861. doi: 10.
1007/s00213-013-3302-7
North, B., and Khakh, R. (2006). P2X receptors as cell-surface ATP sensors in
health and disease. Nature 442, 527–532. doi: 10.1038/nature04886
Okamoto, K., Martin, D. P., Schmelzer, J. D., Mitsui, Y., and Low, P. A. (2001). Pro-
and anti-inflammatory cytokine gene expression in rat sciatic nerve chronic
constriction injury model of neuropathic pain. Exp. Neurol. 169, 386–391.
doi: 10.1006/exnr.2001.7677
Pereira, P., Lazarotto, L., Leal, P., Lopes, T., Morrone, F., and Campos, M.
(2011). Inhibition of phosphatidylinositol-3 kinase γ reduces pruriceptive,
inflammatory, and nociceptive responses induced by trypsin in mice. Pain 152,
2861–2869. doi: 10.1016/j.pain.2011.09.016
Pilat, D., Piotrowska, A., Rojewska, E., Jurga, A., Slusarczyk, J., Makuch, W., et al.
(2016). Blockade of IL-18 signaling diminished neuropathic pain and enhanced
the efficacy of morphine and buprenorphine. Mol. Cell. Neurosci. 71, 114–124.
doi: 10.1016/j.mcn.2015.12.013
Pilat, D., Rojewska, E., Jurga, A. M., Piotrowska, A., Makuch, W., Przewlocka, B.,
et al. (2015). IL-1 receptor antagonist improves morphine and buprenorphine
effi- cacy in a rat neuropathic pain model. Eur. J. Pharmacol. 764, 240–248.
doi: 10.1016/j.ejphar.2015.05.058
Piotrowska, A., Kwiatkowski, K., Rojewska, E., Makuch, W., and Mika, J. (2016).
Maraviroc reduces neuropathic pain through polarization of microglia and
astroglia – Evidence from in vivo and in vitro studies. Neuropharmacology 108,
207–219. doi: 10.1016/j.neuropharm.2016.04.024
Popiolek-Barczyk, K., Kolosowska, N., Piotrowska, A., Makuch, W., Rojewska, E.,
Jurga, A. M., et al. (2015). Parthenolide relieves pain and promotes M2
microglia/macrophage polarization in rat model of neuropathy. Neural Plast.
2015:676473. doi: 10.1155/2015/676473
Popiolek-Barczyk, K., Rojewska, E., Jurga, A. M., Makuch, W., Zador, F.,
Borsodi, A., et al. (2014). Minocycline enhances the effectiveness of
nociceptin/orphanin FQ during neuropathic pain. Biomed Res. Int.
2014:762930. doi: 10.1155/2014/762930
Potucek, Y. D., Crain, J. M., and Watters, J. J. (2006). Purinergic receptors modulate
MAP kinases and transcription factors that control microglial inflammatory
gene expression. Neurochem. Int. 49, 204–214. doi: 10.1016/j.neuint.2006.
04.005
Raghavendra, V., Tanga, F. Y., and DeLeo, J. A. (2004). Complete Freunds
adjuvant-induced peripheral inflammation evokes glial activation and
proinflammatory cytokine expression in the CNS. Eur. J. Neurosci. 20, 467–473.
doi: 10.1111/j.1460-9568.2004.03514.x
Rathinam, V. A. K., Vanaja, S. K., and Fitzgerald, K. A. (2012). Regulation of
inflammasome signaling. Nat. Immunol. 13, 333–342. doi: 10.1038/ni.2237
Rojewska, E., Piotrowska, A., Makuch, W., Przewlocka, B., and Mika, J. (2016).
Pharmacological kynurenine 3-monooxygenase enzyme inhibition significantly
reduces neuropathic pain in a rat model. Neuropharmacology 102, 80–91. doi:
10.1016/j.neuropharm.2015.10.040
Rojewska, E., Popiolek-Barczyk, K., Jurga, A. M., Makuch, W., Przewlocka, B., and
Mika, J. (2014). Involvement of pro- and antinociceptive factors in minocycline
analgesia in rat neuropathic pain model. J. Neuroimmunol. 277, 57–66. doi:
10.1016/j.jneuroim.2014.09.020
Rojewska, E., Popiolek-Barczyk, K., Kolosowska, N., Piotrowska, A.,
Zychowska, M., Makuch, W., et al. (2015). PD98059 influences immune
factors and enhances opioid analgesia in model of neuropathy. PLoS ONE
10:e0138583. doi: 10.1371/journal.pone.0138583
Schonbeck, U., Mach, F., and Libby, P. (1998). Generation of biologically active IL-
1 beta by matrix metalloproteinases: a novel caspase-1-independent pathway of
IL-1 beta processing. J. Immunol. 161, 3340–3346.
Sim, J., and North, R. (2010). Amitriptyline does not block the action of ATP at
human P2X4 receptor. Br. J. Pharmacol. 160, 88–92. doi: 10.1111/j.1476-5381.
2010.00683.x
Tikka, T., Fiebich, B. L., Goldsteins, G., Keinanen, R., and Koistinaho, J. (2001).
Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity
by inhibiting activation and proliferation of microglia. J. Neurosci. 21, 2580–
2588.
Trang, T., and Salter, M. W. (2012). P2X4 purinoceptor signaling in chronic pain.
Purinergic Signal. 8, 621–628. doi: 10.1007/s11302-012-9306-7
Tsuda, M., Mizokoshi, A., Shigemoto-Mogami, Y., Koizumi, S., and Inoue, K.
(2004). Activation of p38 mitogen-activated protein kinase in spinal hyperactive
microglia contributes to pain hypersensitivity following peripheral nerve injury.
Glia 45, 89–95. doi: 10.1002/glia.10308
Tsuda, M., Shigemoto-Mogami, Y., Koizumi, S., Mizokoshi, A., Kohsaka, S., Salter,
M. W., et al. (2003). P2X4 receptors induced in spinal microglia gate tactile
allodynia after nerve injury. Nature 424, 778–783. doi: 10.1038/nature01786
Tsuda, M., Toyomitsu, E., Kometani, M., Tozaki-Saitoh, H., and Inoue, K.
(2009). Mechanisms underlying fibronectin-induced up-regulation of P2X4R
expression in microglia: distinct roles of PI3K-Akt and MEK-ERK signalling
pathways. J. Cell. Mol. Med. 13, 3251–3259. doi: 10.1111/j.1582-4934.2009.
00719.x
Ulmann, L., Hatcher, J. P., Hughes, J. P., Chaumont, S., Green, P. J., Conquet, F.,
et al. (2008). Up-regulation of P2X4 receptors in spinal microglia after
peripheral nerve injury mediates BDNF release and neuropathic pain.
J. Neurosci. 28, 11263–11268. doi: 10.1523/JNEUROSCI.2308-08.2008
Vaccari, J. P. D., Bastien, D., Yurcisin, G., Pineau, I., Dietrich, W. D., De
Koninck, Y., et al. (2012). P2X(4) receptors influence inflammasome activation
after spinal cord injury. J. Neurosci. 32, 3058–3066. doi: 10.1523/Jneurosci.
4930-11.2012
Verri, W. A., Cunha, T. M., Parada, C. A., Poole, S., Liew, F. Y., Ferreira, S. H., et al.
(2007). Antigen-induced inflammatory mechanical hypernociception in mice is
mediated by IL-18. Brain Behav. Immun. 21, 535–543. doi: 10.1016/j.bbi.2006.
11.005
Wilkinson, W. J., and Kemp, P. J. (2011). The carbon monoxide donor, CORM-2, is
an antagonist of ATP-gated, human P2X4 receptors. Purinergic Signal. 7, 57–64.
doi: 10.1007/s11302-010-9213-8
Xu, B., Guan, X. H., Yu, J. X., Lv, J., Zhang, H. X., Fu, Q. C., et al. (2014).
Activation of spinal phosphatidylinositol 3-kinase/protein kinase B mediates
pain behavior induced by plantar incision in mice. Exp. Neurol. 255, 71–82.
doi: 10.1016/j.expneurol.2014.02.019
Yaksh, T., and Rudy, T. (1976). Chronic catheterization of the spinal subarachnoid
space. Physiol. Behav. 17, 1031–1036. doi: 10.1016/0031-9384(76)90029-9
Frontiers in Pharmacology | www.frontiersin.org 17 February 2017 | Volume 8 | Article 48
fphar-08-00048 February 14, 2017 Time: 15:0 # 18
Jurga et al. P2X4R Role in Neuropathic Pain
Zimmermann, M. (1983). Ethical guidelines for investigations of experimental
pain in conscious animals. Pain 16, 109–110. doi: 10.1016/0304-3959(83)
90201-4
Zychowska, M., Rojewska, E., Makuch, W., Luvisetto, S., Pavone, F., Marinelli, S.,
et al. (2016). Participation of pro- and anti-nociceptive interleukins in
botulinum toxin A-induced analgesia in a rat model of neuropathic pain. Eur. J.
Pharmacol. 791, 377–388. doi: 10.1016/j.ejphar.2016.09.019
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
The reviewer LVD and handling Editor declared their shared affiliation, and the
handling Editor states that the process nevertheless met the standards of a fair and
objective review.
Copyright © 2017 Jurga, Piotrowska, Makuch, Przewlocka and Mika. This is an
open-access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) or licensor are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Pharmacology | www.frontiersin.org 18 February 2017 | Volume 8 | Article 48
